RSS

MS Focus: Gilenya Ups Zoster Risk

01 Dec

Risk with fingolimod doubled compared with placebo but still low.

Source: www.medpagetoday.com

What this indicates, again, is that the disease modifying therapies (DMTs) used to delay progress of MS may leave patients susceptible to viral infections, which may prove more opportunistic–and deadly–than in the general population.

 

We are in desperate need of more therapies that do no compromise the immune system, while also helping to reduce the autoimmunity associated with #MS.

See on Scoop.itOvercoming Multiple Sclerosis

Advertisements
 
Leave a comment

Posted by on 1 December 2014 in Uncategorized

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

 
%d bloggers like this: